Anne Thiry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Thiry has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Bernard Masereel
7 shared publications- Claudiu Trandafir Supuran
Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Via U. Schiff 6, Sesto Fiorentino, Firenze, 50019, Italy
7 shared publications Jean-Michel Dogné
4 shared publications- Johan Wouters
Department of Chemistry – NISM University of Namur Namur Belgium
4 shared publications Aurélie Frankart
2 shared publicationsJean-Michel Dogne
2 shared publications
Latest Publications
- 1 January 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 17 (2) , 553-557
Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors
- 1 January 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 17 (2) , 553-557
Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors
- 1 December 2008
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 43 (12) , 2853-2860
Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: Structure–activity relationship and pharmacological evaluation
- 1 December 2008
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 43 (12) , 2853-2860
Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: Structure–activity relationship and pharmacological evaluation
- 4 April 2008
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 44 (2) , 511-518
Synthesis and biological evaluation of a new family of anti-benzylanilinosulfonamides as CA IX inhibitors
- 4 April 2008
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 44 (2) , 511-518
Synthesis and biological evaluation of a new family of anti-benzylanilinosulfonamides as CA IX inhibitors
- 19 March 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (11) , 3051-3056
Recent Developments of Carbonic Anhydrase Inhibitors as Potential Anticancer Drugs
- 19 March 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (11) , 3051-3056
Recent Developments of Carbonic Anhydrase Inhibitors as Potential Anticancer Drugs
- 1 March 2008
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 14 (7) , 661-671
Anticonvulsant Sulfonamides/Sulfamates/Sulfamides with Carbonic Anhydrase Inhibitory Activity: Drug Design and Mechanism of Action
The marketed antiepileptic drugs can not solve entirely the problem of seizure in patients suffering from refractory epilepsies. Therefore, new anticonvulsant compounds structurally and pharmacologically different of the currently prescribed drugs are needed. Carbonic anhydrase (CA) inhibitors are known to act as anticonvulsant since several decades while the link between CA and seizure is not straightforward. However, the recent discovery that several CA isozymes are expressed in brain and the better knowledge of their physiological/ pathological role, lead to the emergence of new CA inhibitors with anticonvulsant effect including: analogues of acetazolamide, analogues of topiramate, aromatic or heterocyclic sulfonamides incorporating valproyl or adamantyl moieties. Different strategies are developed for the design of new more selective CA inhibitors with anticonvulsant properties.
- 1 March 2008
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 14 (7) , 661-671
Anticonvulsant Sulfonamides/Sulfamates/Sulfamides with Carbonic Anhydrase Inhibitory Activity: Drug Design and Mechanism of Action
The marketed antiepileptic drugs can not solve entirely the problem of seizure in patients suffering from refractory epilepsies. Therefore, new anticonvulsant compounds structurally and pharmacologically different of the currently prescribed drugs are needed. Carbonic anhydrase (CA) inhibitors are known to act as anticonvulsant since several decades while the link between CA and seizure is not straightforward. However, the recent discovery that several CA isozymes are expressed in brain and the better knowledge of their physiological/ pathological role, lead to the emergence of new CA inhibitors with anticonvulsant effect including: analogues of acetazolamide, analogues of topiramate, aromatic or heterocyclic sulfonamides incorporating valproyl or adamantyl moieties. Different strategies are developed for the design of new more selective CA inhibitors with anticonvulsant properties.
- 31 August 2007
- Published by Wiley in ChemMedChem
- Vol. 2 (9) , 1273-1280
Exploration of the Binding Mode of Indanesulfonamides as Selective Inhibitors of Human Carbonic Anhydrase Type VII by Targeting Lys 91
Convulsions are common neurological disorders in clinical medicine and are triggered by several mechanisms. The enhancement of neuronal excitability can be related, among other factors, to GABAergic depolarization. Carbonic anhydrase (CA) VII contributes to this electrophysiological behavior by providing bicarbonate anion, which can mediate current through channels coupled to GABAA receptors. Among the cytosolic CAs, the mechanism of action and inhibition of CA VII is less understood. We present herein the pharmacological evaluation of both enantiomers of an indanesulfonamide compound substituted by a pentafluorophenyl moiety against CA VII and five other human CA isoforms to evaluate their selectivity. The investigated compounds are powerful inhibitors of hCA VII, with Ki values in the range of 1.7–3.3 nM, but their selectivity needs to be improved. A molecular modeling study was conducted to rationalize the structure–activity relationships and provide useful insight into the future design of selective hCA VII inhibitors.
- 31 August 2007
- Published by Wiley in ChemMedChem
- Vol. 2 (9) , 1273-1280
Exploration of the Binding Mode of Indanesulfonamides as Selective Inhibitors of Human Carbonic Anhydrase Type VII by Targeting Lys 91
Convulsions are common neurological disorders in clinical medicine and are triggered by several mechanisms. The enhancement of neuronal excitability can be related, among other factors, to GABAergic depolarization. Carbonic anhydrase (CA) VII contributes to this electrophysiological behavior by providing bicarbonate anion, which can mediate current through channels coupled to GABAA receptors. Among the cytosolic CAs, the mechanism of action and inhibition of CA VII is less understood. We present herein the pharmacological evaluation of both enantiomers of an indanesulfonamide compound substituted by a pentafluorophenyl moiety against CA VII and five other human CA isoforms to evaluate their selectivity. The investigated compounds are powerful inhibitors of hCA VII, with Ki values in the range of 1.7–3.3 nM, but their selectivity needs to be improved. A molecular modeling study was conducted to rationalize the structure–activity relationships and provide useful insight into the future design of selective hCA VII inhibitors.
- 1 May 2007
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 7 (9) , 855-864
Carbonic Anhydrase Inhibitors as Anticonvulsant Agents
Seizures is one of the most common neurological disorders in clinical medicine. Triggering mechanisms by which seizures form remain unclear, but are related to a rapid change in ionic composition, including an increase of intracellular potassium concentration and pH shifts within the brain. pH buffering of extra- and intracellular spaces is mainly carried out by the CO2 / HCO3 - buffer, the equilibration of the two species being assured by the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1). Some carbonic anhydrase inhibitors (CAIs) are used as anticonvulsants in the treatment of epilepsy. In this review, we will describe the link between CA and seizures on the basis of several putative mechanisms. Several CA isozymes have been pointed out for their contribution to epileptiform activity. An overview of the CA isozyme expression in the brain and of their specifics roles is also discussed. This article reviews the research achievements published on CA inhibitors, clinically used as anticonvulsant and those under development.
- 1 May 2007
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 7 (9) , 855-864
Carbonic Anhydrase Inhibitors as Anticonvulsant Agents
Seizures is one of the most common neurological disorders in clinical medicine. Triggering mechanisms by which seizures form remain unclear, but are related to a rapid change in ionic composition, including an increase of intracellular potassium concentration and pH shifts within the brain. pH buffering of extra- and intracellular spaces is mainly carried out by the CO2 / HCO3 - buffer, the equilibration of the two species being assured by the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1). Some carbonic anhydrase inhibitors (CAIs) are used as anticonvulsants in the treatment of epilepsy. In this review, we will describe the link between CA and seizures on the basis of several putative mechanisms. Several CA isozymes have been pointed out for their contribution to epileptiform activity. An overview of the CA isozyme expression in the brain and of their specifics roles is also discussed. This article reviews the research achievements published on CA inhibitors, clinically used as anticonvulsant and those under development.